肽受体放射性核素治疗后无进展生存与总生存的预测参数:782例多因素分析
该研究纳入2002年10月至2016年3月在Zentralklinik Bad Berka接受至少3次PRRT的782例神经内分泌肿瘤患者,中位随访36个月,中位PFS为22个月、中位OS为53个月。多因素分析显示Ki-67升高、CgA升高及既往化疗对PFS和OS均有负面影响,既往干扰素-α治疗和糖尿病与PFS较差相关,既往消融和体能状态较差与OS较低相关。
要点
- Ki-67>5%、CgA>336 μg/L、既往干扰素-α或化疗及糖尿病与PFS较低相关。
- Ki-67>10%、CgA>112 μg/L、体能状态≥1、既往化疗或消融与OS较低相关。
- Ki-67、CgA和既往化疗同时影响PFS与OS,可作为PRRT前风险分层参考。
核心结论
- 较高的Ki-67值、较高的CgA水平及既往化疗对PFS和OS均有负面结局。
- PFS还与既往干扰素-α治疗和糖尿病呈负相关,OS较低与既往消融和较高体能状态相关。
研究设计与样本
- 回顾性纳入2002年10月至2016年3月在Zentralklinik Bad Berka接受至少3次PRRT、相邻给药间隔最长6个月的患者。
- 共782例,中位随访36个月,采用Kaplan-Meier曲线及单因素、多因素Cox回归分析PFS和OS相关参数。
主要发现
- 中位PFS为22个月,中位OS为53个月。
- 多因素分析中与PFS较低相关的参数为Ki-67>5%、既往干扰素-α治疗、既往化疗、糖尿病及CgA>336 μg/L。
- 多因素分析中与OS较低相关的参数为Ki-67>10%、体能状态≥1、既往化疗、既往消融及CgA>112 μg/L。
关键数值与推荐
- PFS相关阈值:Ki-67>5%、CgA>336 μg/L。
- OS相关阈值:Ki-67>10%、CgA>112 μg/L、体能状态≥1。
临床怎么用
- PRRT前可结合Ki-67、CgA、既往治疗史、糖尿病及体能状态评估PFS与OS风险。
- 对Ki-67较高、CgA较高或既往化疗的患者,应预期PFS和OS可能较差并加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with neuroendocrine neoplasms. The aim of this study was to identify clinical and treatment parameters associated with progression-free survival (PFS) and overall survival (OS). Methods: All patients treated from October 2002 until March 2016 at the Zentralklinik Bad Berka with at least 3 administrations of PRRT (maximal interval of 6 mo between consecutive administrations) were included. Data were collected in 5 categories: general patient characteristics, tumor characteristics, prior treatments, radioisotope used for PRRT, and blood chemistry. Survival was analyzed using Kaplan-Meier curves. Univariate and multivariate Cox regression analyses were performed to identify parameters associated with PFS and OS. Results: In total, 782 patients were included, with a median follow-up of 36 mo. The median PFS and OS were 22 and 53 mo, respectively. Parameters associated with lower PFS in the multivariate analysis were a Ki-67 of more than 5%, previous treatment with interferon-α and chemotherapy, presence of diabetes, and chromogranin-A (CgA) levels higher than 336 μg/L. Parameters associated with lower OS were a Ki-67 of more than 10%, performance status of at least 1, previous chemotherapy and ablation, and CgA levels higher than 112 μg/L. Conclusion: Higher Ki-67 values, as well as higher CgA levels and previous chemotherapy, had a negative outcome on both PFS and OS. Furthermore, PFS was negatively associated with previous interferon-α treatment and diabetes, whereas lower OS was related to prior ablation and higher performance status.
引用
- Aalbersberg EA, Huizing DMV, Walraven I, et al. Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients. J Nucl Med. 2019. PMID: 30850483. doi:10.2967/jnumed.118.224386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。